Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial

For prostate cancer treatment, treatment options with minimal side effects are desired. External beam radiation therapy (EBRT) is non-invasive, standard of care and delivered in either conventional fractionation over 8 weeks or with moderate hypo-fractionation over about 5 weeks. Recent advances in radiotherapy technology have made extreme hypo-fractionated stereotactic body radiation therapy (SBRT) of prostate cancer feasible, which has not yet been introduced as a standard treatment method in Germany. Initial results from other countries are promising, but long-term results are not yet available. The aim of this study is to investigate feasibility and effectiveness of SBRT for prostate cancer in Germany.

This German bi-center single group trial (HYPOSTAT) is designed to evaluate feasibility and effectiveness, as measured by toxicity and PSA-response, respectively, of an extreme hypo-fractionated SBRT regimen with five fractions of 7 Gy in treatment of localized low and intermediate risk prostate cancer. The target volume includes the prostate with or without the base of seminal vesicles depending on risk stratification and uncertainty margins that are kept at 3-5 mm. SBRT treatment is delivered with the robotic CyberKnife system, which was recently introduced in Germany. Acute and late toxicity after one year will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE v. 4.0), Radiation Therapy Oncology Group (RTOG) and International Prostate Symptom Score (IPSS) Scores. The quality of life will be assessed before and after treatment with the EORTC QLQ C30 questionnaire. Hypothesizing that the proportion of patients with grade 2 side effects or higher is less or equal than 2.8%, thus markedly lower than the standard EBRT percentage (17.5%), the recruitment target is 85 patients.

The HYPOSTAT trial aims at demonstrating short term feasibility of extreme hypo-fractioned SBRT for the treatment of prostate cancer and might be used as the pilot study for a multi-center multi-platform or for randomized-controlled trials comparing conventional radiotherapy with SBRT for localized prostate cancer in the future. The study concept of patient enrollment, follow up and evaluation by multiple public university clinics and actual patient treatment in dedicated private radiosurgery practices with high-tech radiation equipment is unique for clinical trials.

The study is ongoing and currently recruiting patients.

Registration number: NCT02635256 ( clinicaltrials.gov ). Registered 8 December 2015.

Radiation oncology (London, England). 2017 Aug 18*** epublish ***

Ping Jiang, Katja Krockenberger, Reinhard Vonthein, Jane Tereszczuk, Arne Schreiber, Sebastian Liebau, Stefan Huttenlocher, Detlef Imhoff, Panagiotis Balermpas, Christian Keller, Kathrin Dellas, Rene Baumann, Claus Rödel, Guido Hildebrandt, Klaus-Peter Jünemann, Alex S Merseburger, Alan Katz, Andreas Ziegler, Oliver Blanck, Jürgen Dunst

Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Universität zu Lübeck, ZKS, Lübeck, Germany., Saphir Radiochirurgie Zentrum Norddeutschland und Frankfurt am Main, Güstrow, Germany., Klinik für Strahlentherapie, Universitätsklinikum Frankfurt, Frankfurt, Germany., Klinik für Strahlentherapie, Universitätsmedizin Rostock, Rostock, Germany., Klinik für Urologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Klinik für Urologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany., Flushing Radiation Oncology Services, New York, USA., Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe